{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:06:40Z","timestamp":1766020000936,"version":"3.48.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,17]]},"DOI":"10.7759\/cureus.99490","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:04:51Z","timestamp":1766019891000},"source":"Crossref","is-referenced-by-count":0,"title":["Progress in the Application of Pirfenidone in Post-COVID-19 Pulmonary Fibrosis: A Review"],"prefix":"10.7759","author":[{"given":"Xiaolong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/lungindia.lungindia_818_20","article-title":"Post-COVID lung fibrosis: the tsunami that will follow the earthquake","volume":"38","author":"Udwadia ZF","year":"2021","unstructured":"Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: the tsunami that will follow the earthquake. Lung India. 2021, 38:41-7. 10.4103\/lungindia.lungindia_818_20","journal-title":"Lung India"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01445-6","article-title":"SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis","volume":"21","author":"Xu J","year":"2020","unstructured":"Xu J, Xu X, Jiang L, Dua K, Hansbro PM, Liu G. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respir Res. 2020, 21:182. 10.1186\/s12931-020-01445-6","journal-title":"Respir Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202203-0564OC","article-title":"Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the Ukild post-COVID-19 study","volume":"207","author":"Stewart I","year":"2023","unstructured":"Stewart I, Jacob J, George PM, et al.. Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the Ukild post-COVID-19 study. Am J Respir Crit Care Med. 2023, 207:693-703. 10.1164\/rccm.202203-0564OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-12020-z","article-title":"SARS-CoV-2 reinfection in interstitial lung disease patients and its association with clinical deterioration: a two-year prospective cohort study","volume":"25","author":"Wang Y","year":"2025","unstructured":"Wang Y, Wang D, Song Y, Wu N, Du X, Ye Q. SARS-CoV-2 reinfection in interstitial lung disease patients and its association with clinical deterioration: a two-year prospective cohort study. BMC Infect Dis. 2025, 25:1641. 10.1186\/s12879-025-12020-z","journal-title":"BMC Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106592","article-title":"New therapeutic approaches against pulmonary fibrosis","volume":"138","author":"Yu D","year":"2023","unstructured":"Yu D, Xiang Y, Gou T, et al.. New therapeutic approaches against pulmonary fibrosis. Bioorg Chem. 2023, 138:106592. 10.1016\/j.bioorg.2023.106592","journal-title":"Bioorg Chem"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14010051","article-title":"Perspectives on post-COVID-19 pulmonary fibrosis treatment","volume":"14","author":"Cojocaru E","year":"2023","unstructured":"Cojocaru E, Cojocaru T, P\u00eenzariu GM, Vasiliu I, Arma\u0219u I, Cojocaru C. Perspectives on post-COVID-19 pulmonary fibrosis treatment. J Pers Med. 2023, 14:51. 10.3390\/jpm14010051","journal-title":"J Pers Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-02197-5","article-title":"Effects of acute-phase COVID-19-related indicators on pulmonary fibrosis and follow-up evaluation","volume":"29","author":"Wang Q","year":"2024","unstructured":"Wang Q, Zhou Y, Jing F, Feng Y, Ma J, Xue P, Dong Z. Effects of acute-phase COVID-19-related indicators on pulmonary fibrosis and follow-up evaluation. Eur J Med Res. 2024, 29:585. 10.1186\/s40001-024-02197-5","journal-title":"Eur J Med Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/atm.atm_83_23","article-title":"Algorithmic approach in the management of COVID-19 patients with residual pulmonary symptoms","volume":"18","author":"Guri A","year":"2023","unstructured":"Guri A, Groner L, Escalon J, Saleh A. Algorithmic approach in the management of COVID-19 patients with residual pulmonary symptoms. Ann Thorac Med. 2023, 18:167-72. 10.4103\/atm.atm_83_23","journal-title":"Ann Thorac Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080807","article-title":"Lung fibrosis after COVID-19: treatment prospects","volume":"14","author":"Bazdyrev E","year":"2021","unstructured":"Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung fibrosis after COVID-19: treatment prospects. Pharmaceuticals (Basel). 2021, 14:807. 10.3390\/ph14080807","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248957","article-title":"The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT","volume":"16","author":"Zou JN","year":"2021","unstructured":"Zou JN, Sun L, Wang BR, et al.. The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT. PLoS One. 2021, 16:0248957. 10.1371\/journal.pone.0248957","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.atssr.2023.12.019","article-title":"Pulmonary artery vasa vasorum damage in severe COVID-19-induced pulmonary fibrosis","volume":"2","author":"Huang W","year":"2024","unstructured":"Huang W, Richards TD, Kaczorowski DJ, Noda K, Bartholow T, Sanchez PG, Phillippi JA. Pulmonary artery vasa vasorum damage in severe COVID-19-induced pulmonary fibrosis. Ann Thorac Surg Short Rep. 2024, 2:443-7. 10.1016\/j.atssr.2023.12.019","journal-title":"Ann Thorac Surg Short Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26634","article-title":"Discharge may not be the end of treatment: pay attention to pulmonary fibrosis caused by severe COVID-19","volume":"93","author":"Zhang C","year":"2021","unstructured":"Zhang C, Wu Z, Li JW, Tan K, Yang W, Zhao H, Wang GQ. Discharge may not be the end of treatment: pay attention to pulmonary fibrosis caused by severe COVID-19. J Med Virol. 2021, 93:1378-86. 10.1002\/jmv.26634","journal-title":"J Med Virol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00565.2020","article-title":"Role of transient receptor potential vanilloid 4 in therapeutic antifibrotic effects of pirfenidone","volume":"323","author":"Kuronuma K","year":"2022","unstructured":"Kuronuma K, Otsuka M, Wakabayashi M, et al.. Role of transient receptor potential vanilloid 4 in therapeutic antifibrotic effects of pirfenidone. Am J Physiol Lung Cell Mol Physiol. 2022, 323:193-205. 10.1152\/ajplung.00565.2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2438322","article-title":"Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments","volume":"26","author":"Duong-Quy S","year":"2025","unstructured":"Duong-Quy S, Nguyen Hai C, Huynh-Anh T, Nguyen-Nhu V. Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments. Expert Opin Pharmacother. 2025, 26:75-84. 10.1080\/14656566.2024.2438322","journal-title":"Expert Opin Pharmacother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70497","article-title":"Pirfenidone as a cornerstone in the management of fibrotic interstitial lung diseases and its emerging applications: a comprehensive review","volume":"16","author":"Babariya H","year":"2024","unstructured":"Babariya H, Gaidhane SA, Acharya S, Kumar S. Pirfenidone as a cornerstone in the management of fibrotic interstitial lung diseases and its emerging applications: a comprehensive review. Cureus. 2024, 16:70497. 10.7759\/cureus.70497","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/1753466620963015","article-title":"Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients","volume":"14","author":"Feng H","year":"2020","unstructured":"Feng H, Zhao Y, Li Z, Kang J. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Ther Adv Respir Dis. 2020, 14:1753466620963015. 10.1177\/1753466620963015","journal-title":"Ther Adv Respir Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-022-01027-6","article-title":"Pirfenidone and post-covid-19 pulmonary fibrosis: invoked again for realistic goals","volume":"30","author":"Al-Kuraishy HM","year":"2022","unstructured":"Al-Kuraishy HM, Batiha GE, Faidah H, Al-Gareeb AI, Saad HM, Simal-Gandara J. Pirfenidone and post-covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology. 2022, 30:2017-26. 10.1007\/s10787-022-01027-6","journal-title":"Inflammopharmacology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10122387","article-title":"Effect of pirfenidone on risk of pulmonary fibrosis in COVID-19 patients experiencing cytokine storm","volume":"10","author":"Boshra MS","year":"2022","unstructured":"Boshra MS, Abou Warda AE, Sayed MA, Elkomy MH, Alotaibi NH, Mohsen M, Sarhan RM. Effect of pirfenidone on risk of pulmonary fibrosis in COVID-19 patients experiencing cytokine storm. Healthcare (Basel). 2022, 10:2387. 10.3390\/healthcare10122387","journal-title":"Healthcare (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.925703","article-title":"Case report: Pirfenidone in the treatment of post-COVID-19 pulmonary fibrosis","volume":"9","author":"Zhou X","year":"2022","unstructured":"Zhou X, Yang D, Kong X, et al.. Case report: Pirfenidone in the treatment of post-COVID-19 pulmonary fibrosis. Front Med (Lausanne). 2022, 9:925703. 10.3389\/fmed.2022.925703","journal-title":"Front Med (Lausanne)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13923","article-title":"Pulmonary fibrosis after COVID-19 pneumonia","volume":"13","author":"Malik B","year":"2021","unstructured":"Malik B, Abdelazeem B, Ghatol A. Pulmonary fibrosis after COVID-19 pneumonia. Cureus. 2021, 13:13923. 10.7759\/cureus.13923","journal-title":"Cureus"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2022.2143","article-title":"Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series","volume":"93","author":"Iturbe Esquivel B","year":"2022","unstructured":"Iturbe Esquivel B, Meneses Calder\u00f3n J, Concepci\u00f3n Carrillo LE, Mendieta Zeron H. Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series. Monaldi Arch Chest Dis. 2022, 93:10.4081\/monaldi.2022.2143","journal-title":"Monaldi Arch Chest Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02249-2024","article-title":"Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial","volume":"65","author":"Bermudo-Peloche G","year":"2025","unstructured":"Bermudo-Peloche G, Del Rio B, Vicens-Zygmunt V, et al.. Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial. Eur Respir J. 2025, 65:2402249. 10.1183\/13993003.02249-2024","journal-title":"Eur Respir J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107362","article-title":"Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy","volume":"217","author":"Sansores RH","year":"2023","unstructured":"Sansores RH, Ram\u00edrez-Venegas A, Montiel-Lopez F, et al.. Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy. Respir Med. 2023, 217:107362. 10.1016\/j.rmed.2023.107362","journal-title":"Respir Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2024.102287","article-title":"The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study","volume":"84","author":"Zhao R","year":"2024","unstructured":"Zhao R, Xie B, Wang X, Zhang X, Ren Y, Wang C, Dai H. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study. Pulm Pharmacol Ther. 2024, 84:102287. 10.1016\/j.pupt.2024.102287","journal-title":"Pulm Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.26442\/00403660.2020.08.000767","article-title":"Novel coronavirus infection COVID-19: extrapulmonary manifestations (Article in Russian)","volume":"92","author":"Maev IV","year":"2020","unstructured":"Maev IV, Shpektor AV, Vasilyeva EY, Manchurov VN, Andreev DN. Novel coronavirus infection COVID-19: extrapulmonary manifestations (Article in Russian). Ter Arkh. 2020, 92:4-11. 10.26442\/00403660.2020.08.000767","journal-title":"Ter Arkh"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1134\/S1019331622040062","article-title":"Coronavirus infection 2019 (COVID-19) and autoimmunity","volume":"92","author":"Nasonov EL","year":"2022","unstructured":"Nasonov EL, Samsonov MY, Lila AM. Coronavirus infection 2019 (COVID-19) and autoimmunity. Her Russ Acad Sci. 2022, 92:398-403. 10.1134\/S1019331622040062","journal-title":"Her Russ Acad Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11040895","article-title":"Idiopathic pulmonary fibrosis and post-COVID-19 lung fibrosis: links and risks","volume":"11","author":"Patrucco F","year":"2023","unstructured":"Patrucco F, Solidoro P, Gavelli F, Apostolo D, Bellan M. Idiopathic pulmonary fibrosis and post-COVID-19 lung fibrosis: links and risks. Microorganisms. 2023, 11:895. 10.3390\/microorganisms11040895","journal-title":"Microorganisms"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112147-20241202-00713","article-title":"Progressive fibrosing interstitial lung disease which means idiopathic pulmonary fibrosis plus progressive pulmonary fibrosis (Article in Chinese)","volume":"48","author":"Xu WS","year":"2025","unstructured":"Xu WS, Mu XD. Progressive fibrosing interstitial lung disease which means idiopathic pulmonary fibrosis plus progressive pulmonary fibrosis (Article in Chinese). Zhonghua Jie He He Hu Xi Za Zhi. 2025, 48:592-3. 10.3760\/cma.j.cn112147-20241202-00713","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-02847-7","article-title":"Function of epithelial stem cell in the repair of alveolar injury","volume":"13","author":"Chan M","year":"2022","unstructured":"Chan M, Liu Y. Function of epithelial stem cell in the repair of alveolar injury. Stem Cell Res Ther. 2022, 13:170. 10.1186\/s13287-022-02847-7","journal-title":"Stem Cell Res Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104501","article-title":"The link between rheumatic disorders and inborn errors of immunity","volume":"90","author":"Sogkas G","year":"2023","unstructured":"Sogkas G, Witte T. The link between rheumatic disorders and inborn errors of immunity. EBioMedicine. 2023, 90:104501. 10.1016\/j.ebiom.2023.104501","journal-title":"EBioMedicine"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-022-00781-z","article-title":"circHECTD1 attenuates apoptosis of alveolar epithelial cells in acute lung injury","volume":"102","author":"Li H","year":"2022","unstructured":"Li H, Niu X, Shi H, et al.. circHECTD1 attenuates apoptosis of alveolar epithelial cells in acute lung injury. Lab Invest. 2022, 102:945-56. 10.1038\/s41374-022-00781-z","journal-title":"Lab Invest"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.5152\/dir.2020.20212","article-title":"Chest CT findings in patients with coronavirus disease 2019 (COVID-19): a comprehensive review","volume":"27","author":"Li J","year":"2021","unstructured":"Li J, Yan R, Zhai Y, Qi X, Lei J. Chest CT findings in patients with coronavirus disease 2019 (COVID-19): a comprehensive review. Diagn Interv Radiol. 2021, 27:621-32. 10.5152\/dir.2020.20212","journal-title":"Diagn Interv Radiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.4103\/jgid.jgid_150_23","article-title":"The diagnostic and predictive value of biomarkers for pulmonary fibrosis in patients with coronavirus disease 2019","volume":"16","author":"Lv J","year":"2024","unstructured":"Lv J, Liping C, Huaying W. The diagnostic and predictive value of biomarkers for pulmonary fibrosis in patients with coronavirus disease 2019. J Glob Infect Dis. 2024, 16:45-53. 10.4103\/jgid.jgid_150_23","journal-title":"J Glob Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103590","article-title":"Post COVID-19 pulmonary fibrosis; a meta-analysis study","volume":"77","author":"Hama Amin BJ","year":"2022","unstructured":"Hama Amin BJ, Kakamad FH, Ahmed GS, et al.. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Ann Med Surg (Lond). 2022, 77:103590. 10.1016\/j.amsu.2022.103590","journal-title":"Ann Med Surg (Lond)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinimag.2021.03.030","article-title":"Interstitial lung abnormalities and pulmonary fibrosis in COVID-19 patients: a short-term follow-up case series","volume":"77","author":"Gulati A","year":"2021","unstructured":"Gulati A, Lakhani P. Interstitial lung abnormalities and pulmonary fibrosis in COVID-19 patients: a short-term follow-up case series. Clin Imaging. 2021, 77:180-6. 10.1016\/j.clinimag.2021.03.030","journal-title":"Clin Imaging"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56616","article-title":"COVID-19 chest manifestation on CT scan and associated risk factors for developing pulmonary fibrosis","volume":"16","author":"Bakhsh N","year":"2024","unstructured":"Bakhsh N, Banjar M. COVID-19 chest manifestation on CT scan and associated risk factors for developing pulmonary fibrosis. Cureus. 2024, 16:56616. 10.7759\/cureus.56616","journal-title":"Cureus"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2020.0215","article-title":"Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia","volume":"21","author":"Yu M","year":"2020","unstructured":"Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol. 2020, 21:746-55. 10.3348\/kjr.2020.0215","journal-title":"Korean J Radiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202501-049OC","article-title":"Imaging, pulmonary function, and histopathologic findings of persistent fibrosis in a longitudinal cohort 3 years after COVID-19","volume":"22","author":"Murphy SO","year":"2025","unstructured":"Murphy SO, McGroder CF, Salvatore MM, et al.. Imaging, pulmonary function, and histopathologic findings of persistent fibrosis in a longitudinal cohort 3 years after COVID-19. Ann Am Thorac Soc. 2025, 22:1654-63. 10.1513\/AnnalsATS.202501-049OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1101\/2024.10.16.24315602","article-title":"Imaging, pulmonary function, and histopathologic findings of persistent fibrosis in a longitudinal cohort three years after severe COVID-19 infection (Preprint)","author":"Murphy SO","year":"2024","unstructured":"Murphy SO, McGroder CF, Salvatore MM, et al.. Imaging, pulmonary function, and histopathologic findings of persistent fibrosis in a longitudinal cohort three years after severe COVID-19 infection (Preprint). medRxiv. 2024, 10.1101\/2024.10.16.24315602","journal-title":"medRxiv"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206879","article-title":"Fatal pulmonary fibrosis: a post-COVID-19 autopsy case (Preprint)","author":"Schwensen HF","year":"2020","unstructured":"Schwensen HF, Borreschmidt LK, Storgaard M, Redsted S, Christensen S, Madsen LB. Fatal pulmonary fibrosis: a post-COVID-19 autopsy case (Preprint). J Clin Pathol. 2020, 10.1136\/jclinpath-2020-206879","journal-title":"J Clin Pathol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025232","article-title":"Correlation of autopsy pathological findings and imaging features from 9 fatal cases of COVID-19 pneumonia","volume":"100","author":"Zhao L","year":"2021","unstructured":"Zhao L, Wang X, Xiong Y, Fan Y, Zhou Y, Zhu W. Correlation of autopsy pathological findings and imaging features from 9 fatal cases of COVID-19 pneumonia. Medicine (Baltimore). 2021, 100:25232. 10.1097\/MD.0000000000025232","journal-title":"Medicine (Baltimore)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14961","article-title":"Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography","volume":"75","author":"Acat M","year":"2021","unstructured":"Acat M, Yildiz Gulhan P, Oner S, Turan MK. Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography. Int J Clin Pract. 2021, 75:14961. 10.1111\/ijcp.14961","journal-title":"Int J Clin Pract"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2022.12.021","article-title":"Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: a randomized, prospective study","volume":"160","author":"Kerget B","year":"2023","unstructured":"Kerget B, \u00c7il G, Araz \u00d6, Alper F, Akg\u00fcn M. Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: a randomized, prospective study. Med Clin (Barc). 2023, 160:525-30. 10.1016\/j.medcli.2022.12.021","journal-title":"Med Clin (Barc)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.4103\/lungindia.lungindia_568_21","article-title":"A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities","volume":"39","author":"Dhooria S","year":"2022","unstructured":"Dhooria S, Maturu VN, Talwar D, et al.. A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities. Lung India. 2022, 39:254-60. 10.4103\/lungindia.lungindia_568_21","journal-title":"Lung India"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2025.3301","article-title":"Impact of antifibrotics on post-COVID-19 lung sequelae (Preprint)","author":"Akl YM","year":"2025","unstructured":"Akl YM, Soliman YA, Mohamed SA, Abdelghaffar AN, Bayoumi AI. Impact of antifibrotics on post-COVID-19 lung sequelae (Preprint). Monaldi Arch Chest Dis. 2025, 10.4081\/monaldi.2025.3301","journal-title":"Monaldi Arch Chest Dis"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112147-20200326-00419","article-title":"Expert recommendations for the diagnosis and treatment of interstitial lung disease caused by novel coronavirus pneumonia (Article in Chinese)","volume":"43","year":"2020","unstructured":"Expert recommendations for the diagnosis and treatment of interstitial lung disease caused by novel coronavirus pneumonia (Article in Chinese). Zhonghua Jie He He Hu Xi Za Zhi. 2020, 43.827-33. 10.3760\/cma.j.cn112147-20200326-00419","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10070498","article-title":"COVID-19 pneumonia: three thoracic complications in the same patient","volume":"10","author":"Borghesi A","year":"2020","unstructured":"Borghesi A, Aggiusti C, Farina D, Maroldi R, Muiesan ML. COVID-19 pneumonia: three thoracic complications in the same patient. Diagnostics (Basel). 2020, 10:498. 10.3390\/diagnostics10070498","journal-title":"Diagnostics (Basel)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000001152","article-title":"An updated review of pulmonary radiological features of acute and chronic COVID-19","volume":"31","author":"Tcheroyan R","year":"2025","unstructured":"Tcheroyan R, Makhoul P, Simpson S. An updated review of pulmonary radiological features of acute and chronic COVID-19. Curr Opin Pulm Med. 2025, 31:183-95. 10.1097\/MCP.0000000000001152","journal-title":"Curr Opin Pulm Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.8045","article-title":"Pirfenidone activates cannabinoid receptor 2 in a mouse model of bleomycin-induced pulmonary fibrosis","volume":"18","author":"Liu J","year":"2019","unstructured":"Liu J, Shi G. Pirfenidone activates cannabinoid receptor 2 in a mouse model of bleomycin-induced pulmonary fibrosis. Exp Ther Med. 2019, 18:4241-8. 10.3892\/etm.2019.8045","journal-title":"Exp Ther Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/cimb44100323","article-title":"Cytokine patterns in COVID-19 patients: which cytokines predict mortality and which protect against?","volume":"44","author":"Basheer M","year":"2022","unstructured":"Basheer M, Saad E, Kananeh M, et al.. Cytokine patterns in COVID-19 patients: which cytokines predict mortality and which protect against?. Curr Issues Mol Biol. 2022, 44:4735-47. 10.3390\/cimb44100323","journal-title":"Curr Issues Mol Biol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1335","article-title":"Pirfenidone use in fibrotic diseases: what do we know so far?","volume":"12","author":"Torre A","year":"2024","unstructured":"Torre A, Mart\u00ednez-S\u00e1nchez FD, Narvaez-Ch\u00e1vez SM, Herrera-Islas MA, Aguilar-Salinas CA, C\u00f3rdova-Gallardo J. Pirfenidone use in fibrotic diseases: what do we know so far?. Immun Inflamm Dis. 2024, 12:1335. 10.1002\/iid3.1335","journal-title":"Immun Inflamm Dis"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021461","article-title":"Antifibrotic effects of caffeine, curcumin and pirfenidone in primary human keratocytes","volume":"24","author":"Talpan D","year":"2023","unstructured":"Talpan D, Salla S, Seidelmann N, Walter P, Fuest M. Antifibrotic effects of caffeine, curcumin and pirfenidone in primary human keratocytes. Int J Mol Sci. 2023, 24:1461. 10.3390\/ijms24021461","journal-title":"Int J Mol Sci"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1426.2019.03.007","article-title":"Antifibrotic effect of pirfenidone on orbital fibroblasts in patients with thyroid-associated ophthalmopathy and its mechanisms (Article in Chinese)","volume":"58","author":"Li DD","year":"2019","unstructured":"Li DD, Liu Y, Yuan RR, Yu T, Yang B, Pang WY. Antifibrotic effect of pirfenidone on orbital fibroblasts in patients with thyroid-associated ophthalmopathy and its mechanisms (Article in Chinese). Zhonghua Nei Ke Za Zhi. 2019, 58:185-90. 10.3760\/cma.j.issn.0578-1426.2019.03.007","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02631-9","article-title":"Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer","volume":"130","author":"Lei Y","year":"2024","unstructured":"Lei Y, Xu J, Xiao M, et al.. Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer. Br J Cancer. 2024, 130:1505-16. 10.1038\/s41416-024-02631-9","journal-title":"Br J Cancer"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28020753","article-title":"Cepharanthine ameliorates pulmonary fibrosis by inhibiting the NF-\u03bab\/NLRP3 pathway, fibroblast-to-myofibroblast transition and inflammation","volume":"28","author":"Chen G","year":"2023","unstructured":"Chen G, Li J, Liu H, et al.. Cepharanthine ameliorates pulmonary fibrosis by inhibiting the NF-\u03bab\/NLRP3 pathway, fibroblast-to-myofibroblast transition and inflammation. Molecules. 2023, 28:753. 10.3390\/molecules28020753","journal-title":"Molecules"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1171-2","article-title":"Interferon-\u03b3 enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation","volume":"20","author":"Vu TN","year":"2019","unstructured":"Vu TN, Chen X, Foda HD, Smaldone GC, Hasaneen NA. Interferon-\u03b3 enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation. Respir Res. 2019, 20:206. 10.1186\/s12931-019-1171-2","journal-title":"Respir Res"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.103819","article-title":"Pirfenidone encapsulated in succinylated gelatin-coated liposomes exhibits sustained antifibrotic effects in vitro models of renal, pulmonary, and hepatic fibrosis","volume":"114","author":"Togami K","year":"2025","unstructured":"Togami K, Kanehira Y, Nakamura Y, et al.. Pirfenidone encapsulated in succinylated gelatin-coated liposomes exhibits sustained antifibrotic effects in vitro models of renal, pulmonary, and hepatic fibrosis. J Pharm Sci. 2025, 114:103819. 10.1016\/j.xphs.2025.103819","journal-title":"J Pharm Sci"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00295.2024","article-title":"p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone","volume":"329","author":"Fan L","year":"2025","unstructured":"Fan L, Shetty RS, Dao HM, et al.. p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone. Am J Physiol Lung Cell Mol Physiol. 2025, 329:480-98. 10.1152\/ajplung.00295.2024","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29435","article-title":"Effectiveness and safety of pirfenidone and nintedanib for pulmonary fibrosis in COVID-19-induced severe pneumonia: an interventional study","volume":"14","author":"Choudhary R","year":"2022","unstructured":"Choudhary R, Kumar A, Ali O, Pervez A. Effectiveness and safety of pirfenidone and nintedanib for pulmonary fibrosis in COVID-19-induced severe pneumonia: an interventional study. Cureus. 2022, 14:29435. 10.7759\/cureus.29435","journal-title":"Cureus"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.11.035","article-title":"Comparison of pirfenidone and nintedanib: post hoc analysis of the cleanup-IPF study","volume":"165","author":"Kim JS","year":"2024","unstructured":"Kim JS, Murray S, Yow E, et al.. Comparison of pirfenidone and nintedanib: post hoc analysis of the cleanup-IPF study. Chest. 2024, 165:1163-73. 10.1016\/j.chest.2023.11.035","journal-title":"Chest"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14890","article-title":"Tofacitinib and pirfenidone as rescue therapies for severe COVID-19 in a patient with previously stable interstitial lung disease associated with Sj\u00f6gren syndrome","volume":"27","author":"Tsao YC","year":"2024","unstructured":"Tsao YC, Chuang SH, Tseng CW. Tofacitinib and pirfenidone as rescue therapies for severe COVID-19 in a patient with previously stable interstitial lung disease associated with Sj\u00f6gren syndrome. Int J Rheum Dis. 2024, 27:14890. 10.1111\/1756-185X.14890","journal-title":"Int J Rheum Dis"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.581828","article-title":"Long-term follow-up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: a real-life comparison study","volume":"7","author":"Cameli P","year":"2020","unstructured":"Cameli P, Refini RM, Bergantini L, et al.. Long-term follow-up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: a real-life comparison study. Front Mol Biosci. 2020, 7:581828. 10.3389\/fmolb.2020.581828","journal-title":"Front Mol Biosci"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123229","article-title":"Long-term safety of antifibrotic drugs in IPF: a real-world experience","volume":"10","author":"Levra S","year":"2022","unstructured":"Levra S, Guida G, Sprio AE, et al.. Long-term safety of antifibrotic drugs in IPF: a real-world experience. Biomedicines. 2022, 10:3229. 10.3390\/biomedicines10123229","journal-title":"Biomedicines"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24985-x","article-title":"Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGF\u03b2-induced lung fibrosis","volume":"12","author":"Ebrahimpour A","year":"2022","unstructured":"Ebrahimpour A, Ahir M, Wang M, et al.. Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGF\u03b2-induced lung fibrosis. Sci Rep. 2022, 12:20668. 10.1038\/s41598-022-24985-x","journal-title":"Sci Rep"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61050857","article-title":"Baricitinib mitigates methotrexate-induced liver fibrosis model via YAP pathway","volume":"61","author":"Ulusan M","year":"2025","unstructured":"Ulusan M, Erdogan MA, Simsek O, Dogan Z, Ciftci BB, Atalan G, Erbas O. Baricitinib mitigates methotrexate-induced liver fibrosis model via YAP pathway. Medicina (Kaunas). 2025, 61:857. 10.3390\/medicina61050857","journal-title":"Medicina (Kaunas)"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1039\/d2bm00242f","article-title":"A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis","volume":"10","author":"Ullah A","year":"2022","unstructured":"Ullah A, Chen G, Yibang Z, et al.. A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis. Biomater Sci. 2022, 10:2650-64. 10.1039\/d2bm00242f","journal-title":"Biomater Sci"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.04.002","article-title":"Sorafenib-loaded silica-containing redox nanoparticles for oral anti-liver fibrosis therapy","volume":"345","author":"Tran HT","year":"2022","unstructured":"Tran HT, Vong LB, Nishikawa Y, Nagasaki Y. Sorafenib-loaded silica-containing redox nanoparticles for oral anti-liver fibrosis therapy. J Control Release. 2022, 345:880-91. 10.1016\/j.jconrel.2022.04.002","journal-title":"J Control Release"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1007\/s11259-024-10493-y","article-title":"Pirfenidone inhibits TGF-\u03b21-induced fibrosis via downregulation of Smad and ERK pathway in MDCK cells","volume":"48","author":"Im CY","year":"2024","unstructured":"Im CY, Kim SH, Song KH, Ryu MO, Youn HY, Seo KW. Pirfenidone inhibits TGF-\u03b21-induced fibrosis via downregulation of Smad and ERK pathway in MDCK cells. Vet Res Commun. 2024, 48:3167-76. 10.1007\/s11259-024-10493-y","journal-title":"Vet Res Commun"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.935","article-title":"Therapeutic induction of Bcl2-associated athanogene 3-mediated autophagy in idiopathic pulmonary fibrosis","volume":"12","author":"Chillappagari S","year":"2022","unstructured":"Chillappagari S, Schwarz J, Kesireddy V, et al.. Therapeutic induction of Bcl2-associated athanogene 3-mediated autophagy in idiopathic pulmonary fibrosis. Clin Transl Med. 2022, 12:935. 10.1002\/ctm2.935","journal-title":"Clin Transl Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114005","article-title":"Pulmonary surfactant-based pirfenidone-loaded nanovesicles for inhalation therapy of idiopathic pulmonary fibrosis","volume":"385","author":"Kim CG","year":"2025","unstructured":"Kim CG, Jang M, Oh C, et al.. Pulmonary surfactant-based pirfenidone-loaded nanovesicles for inhalation therapy of idiopathic pulmonary fibrosis. J Control Release. 2025, 385:114005. 10.1016\/j.jconrel.2025.114005","journal-title":"J Control Release"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.593620","article-title":"Low-dose of intrapulmonary pirfenidone improves human transforming growth factor\u03b21-driven lung fibrosis","volume":"11","author":"Okano T","year":"2020","unstructured":"Okano T, Kobayashi T, Yasuma T, et al.. Low-dose of intrapulmonary pirfenidone improves human transforming growth factor\u03b21-driven lung fibrosis. Front Pharmacol. 2020, 11:593620. 10.3389\/fphar.2020.593620","journal-title":"Front Pharmacol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.4155\/tde-2023-0045","article-title":"Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment","volume":"14","author":"Zarogoulidis P","year":"2023","unstructured":"Zarogoulidis P, Petridis D, Huang H, et al.. Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment. Ther Deliv. 2023, 14:491-8. 10.4155\/tde-2023-0045","journal-title":"Ther Deliv"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2018-001806","article-title":"Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis","volume":"27","author":"Marcos Ribes B","year":"2020","unstructured":"Marcos Ribes B, Sancho-Chust JN, Talens A, Arlandis M, Herraiz P, Chiner E, Aznar T. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis. Eur J Hosp Pharm. 2020, 27:350-4. 10.1136\/ejhpharm-2018-001806","journal-title":"Eur J Hosp Pharm"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202211_30377","article-title":"The efficacy and safety of pirfenidone in the treatment of HPS-related pulmonary fibrosis and Idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"26","author":"Ma YJ","year":"2022","unstructured":"Ma YJ, Zhang Q, Wang CX, Wu W. The efficacy and safety of pirfenidone in the treatment of HPS-related pulmonary fibrosis and Idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022, 26:8411-24. 10.26355\/eurrev_202211_30377","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-1121-2","article-title":"Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis","volume":"20","author":"Shi H","year":"2020","unstructured":"Shi H, Yin D, Bonella F, et al.. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC Pulm Med. 2020, 20:128. 10.1186\/s12890-020-1121-2","journal-title":"BMC Pulm Med"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114472","article-title":"Thiazole isomers as potential ALK5 inhibitors alleviate P2X7R-mediated inflammation during liver fibrosis","volume":"153","author":"Jiang XL","year":"2025","unstructured":"Jiang XL, Liu C, Zhan ZY, et al.. Thiazole isomers as potential ALK5 inhibitors alleviate P2X7R-mediated inflammation during liver fibrosis. Int Immunopharmacol. 2025, 153:114472. 10.1016\/j.intimp.2025.114472","journal-title":"Int Immunopharmacol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24193601","article-title":"Combination therapy strategies for the treatment of malaria","volume":"24","author":"Alven S","year":"2019","unstructured":"Alven S, Aderibigbe B. Combination therapy strategies for the treatment of malaria. Molecules. 2019, 24:3601. 10.3390\/molecules24193601","journal-title":"Molecules"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.248062","article-title":"Combination strategies to improve targeted radionuclide therapy","volume":"61","author":"Chan TG","year":"2020","unstructured":"Chan TG, O'Neill E, Habjan C, Cornelissen B. Combination strategies to improve targeted radionuclide therapy. J Nucl Med. 2020, 61:1544-52. 10.2967\/jnumed.120.248062","journal-title":"J Nucl Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2024.05.011","article-title":"Combination strategies and targeted radionuclide therapies","volume":"54","author":"Jewell K","year":"2024","unstructured":"Jewell K, Kostos L, Emmerson B, Hofman MS. Combination strategies and targeted radionuclide therapies. Semin Nucl Med. 2024, 54:612-21. 10.1053\/j.semnuclmed.2024.05.011","journal-title":"Semin Nucl Med"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-14286-4","article-title":"Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis","volume":"15","author":"Xu J","year":"2025","unstructured":"Xu J, Abudureheman Z, Gong H, Zhong X, Xue L, Zou X, Li L. Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis. Sci Rep. 2025, 15:28339. 10.1038\/s41598-025-14286-4","journal-title":"Sci Rep"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13731","article-title":"Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice","volume":"18","author":"Liu N","year":"2024","unstructured":"Liu N, Song Y, Liu T, Wang H, Yu N, Ma H. Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice. Clin Respir J. 2024, 18:13731. 10.1111\/crj.13731","journal-title":"Clin Respir J"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.12890\/2021_002821","article-title":"Delayed use of the recombinant human IL-1 receptor antagonist anakinra in five Covid-19 patients with pulmonary fibrosis and persistent hypoxaemia: a preliminary report","volume":"8","author":"Nan D","year":"2021","unstructured":"Nan D, Abraira-Meriel C, de la Roz-Fern\u00e1ndez S, Maestre-Orozco T, Hernandez JL, Fernandez-Ayala M. Delayed use of the recombinant human IL-1 receptor antagonist anakinra in five Covid-19 patients with pulmonary fibrosis and persistent hypoxaemia: a preliminary report. Eur J Case Rep Intern Med. 2021, 8:002821. 10.12890\/2021_002821","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18573","article-title":"Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone","volume":"9","author":"Kubbara A","year":"2023","unstructured":"Kubbara A, Amundson WH, Herman A, Lee AM, Bishop JR, Kim HJ. Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone. Heliyon. 2023, 9:18573. 10.1016\/j.heliyon.2023.e18573","journal-title":"Heliyon"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080819","article-title":"Pharmacological interactions of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis in times of COVID-19 pandemic","volume":"14","author":"Serra L\u00f3pez-Matencio JM","year":"2021","unstructured":"Serra L\u00f3pez-Matencio JM, G\u00f3mez M, Vicente-Rabaneda EF, Gonz\u00e1lez-Gay MA, Ancochea J, Casta\u00f1eda S. Pharmacological interactions of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis in times of COVID-19 pandemic. Pharmaceuticals (Basel). 2021, 14:819. 10.3390\/ph14080819","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202103-342OC","article-title":"Pirfenidone in progressive pulmonary fibrosis: a systematic review and meta-analysis","volume":"19","author":"Ghazipura M","year":"2022","unstructured":"Ghazipura M, Mammen MJ, Bissell BD, et al.. Pirfenidone in progressive pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc. 2022, 19:1030-9. 10.1513\/AnnalsATS.202103-342OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3390\/arm93040024","article-title":"Pharmacological immunomodulation via collagen-polyvinylpyrrolidone or pirfenidone plays a role in the recovery of patients with severe COVID-19 through similar mechanisms of action involving the JAK\/STAT signalling pathway: a pilot study","volume":"93","author":"Mendieta-Zer\u00f3n H","year":"2025","unstructured":"Mendieta-Zer\u00f3n H, Cruz-Arenas E, D\u00edaz-Meza S, et al.. Pharmacological immunomodulation via collagen-polyvinylpyrrolidone or pirfenidone plays a role in the recovery of patients with severe COVID-19 through similar mechanisms of action involving the JAK\/STAT signalling pathway: a pilot study. Adv Respir Med. 2025, 93:24. 10.3390\/arm93040024","journal-title":"Adv Respir Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/445028-progress-in-the-application-of-pirfenidone-in-post-covid-19-pulmonary-fibrosis-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:04:55Z","timestamp":1766019895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/445028-progress-in-the-application-of-pirfenidone-in-post-covid-19-pulmonary-fibrosis-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":86,"URL":"https:\/\/doi.org\/10.7759\/cureus.99490","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}